Can Patients With Relapsed, Previously Untreated, Stage I Epithelial Ovarian Cancer Be Successfully Treated With Salvage Therapy?

Kolomainen, D; A’Hern, Roger; Coxon, Fareeda Y.; Fisher, Cyril; King, David M.; Blake, Peter; Barton, Desmond P.J.; Shepherd, John H.; Kaye, Stanley B.; Gore, Martin

doi:10.1200/jco.2003.06.119

Cited by 35 publications

(21 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9,10,15,16,18Y22 Very few articles have specifically assessed the clinical outcome of patients with early-stage epithelial ovarian cancer who will ultimately develop recurrent disease following surgery with 23 or without adjuvant therapy. 24 The aim of this multicenter retrospective Italian study was to analyze the survival after recurrence and the clinical outcome of patients with recurrent early-stage epithelial ovarian cancer.…”

mentioning

confidence: 99%

Prognostic Factors and Clinical Outcome of Patients With Recurrent Early-Stage Epithelial Ovarian Cancer: An Italian Multicenter Retrospective Study

Gadducci

Cosio

Zola

et al. 2013

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Prognostic Factors and Clinical Outcome of Patients With Recurrent Early-Stage Epithelial Ovarian Cancer: An Italian Multicenter Retrospective Study

Gadducci

Cosio

Zola

et al. 2013

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…6 In contrast, patients with high-risk (stage IA-IB grade 3, stage IC, stage II), early-stage ovarian cancer appear to benefit from adjuvant chemotherapy. 1,[7][8][9][10] The benefit of chemotherapy for subsets of patients with early-stage ovarian cancer has subsequently been confirmed in several trials. 3,10,11 Although there is general consensus about the use of adjuvant chemotherapy in high-risk early-stage patients, there is debate about the optimal duration of chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer

Dinkelspiel

Zimmerman

Lewin

et al. 2014

Gynecologic Oncology

View full text Add to dashboard Cite

Objective-Although 5-year survival for early-stage ovarian cancer is favorable, prognosis at recurrence is poor, necessitating appropriate initial management. We examined the patterns of care and the impact of the duration of chemotherapy on survival for women with early-stage ovarian cancer.Methods-We used the SEER-Medicare database to identify women ≥65 years of age with stage I ovarian cancer diagnosed from 1992-2009. Patients were categorized as low-risk (non-clear cell histology, stage IA or IB, grade 1 or 2) or high-risk (clear cell histology, grade 3, or stage IC). We used multivariable logistic regression models to determine predictors of chemotherapy use and duration and Cox proportional hazards models to evaluate the effect of chemotherapy use and duration on survival.Results-We identified 1394 patients. Among low-risk patients, 32.9% received adjuvant chemotherapy and the use of chemotherapy increased with time. Among high-risk patients, 71.9% received adjuvant chemotherapy; 44.2% had ≤ 3 months of treatment, and 55.8% had >3 months of treatment. Older patients were less likely to receive chemotherapy, while those with higher Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. HHS Public Access

show abstract

“…Все больные получали адъювантную хи миотерапию и рецидивы заболевания по ка не обнаружены. Положительная роль адъювантной химиотерапии препаратами платины доказана в исследованиях ICON 1, EORTCI ACTION 2002 для групп боль ных с высоким риском развития рецидива или псевдомиксомы брюшины [23].…”

Section: Discussionunclassified

Clinical and Molecular Aspects of Mucinous Ovarian Tumors: Etiopathogenesis, Individualization of Treatment

Кедрова¹,

Levakov²,

Shablovskiy³

et al. 2010

Journal of Clinical Practice

View full text Add to dashboard Cite

В течение нескольких лет имеет место дублирование работ, направленных на об наружение наиболее эффективных прог рамм диагностики и лечения опухолей яичников (ОЯ). Разочаровывающие ре зультаты общей выживаемости больных раком яичников (РЯ) после современной стандартной терапии даже при оптималь ной циторедуктивной операции заставля ют искать новые пути совершенствования и индивидуализации лечения. В этом по могают уже известные факторы прогноза, которые подразделяются на несколько больших групп.Опухолевый фактор включает распро страненность, гистологический тип, сте пень инвазии, дифференцировки и плоид ность опухоли.Лечебные факторы можно подразде лить на хирургический, включающий радикальность операции, ее объем и трав матичность, и лекарственный, зависящий от чувствительности опухоли к химио терапии. Для определения прогноза и оценки факторов, влияющих на подбор индивидуального лечения, ретроспективно проанализировано 34 истории болезни пациенток с муцинозными опухолями яичников (МОЯ), имеющих высокий риск развития псевдомиксомы брюшины. Выявили, что МОЯ имеют клинические, биохимические и гистоиммунохимические особенности, позволяющие прогнозировать риск рецидива и индивидуализировать лечение. КЛИНИКО МОЛЕКУЛЯРНЫЕ АСПЕКТЫКлючевые слова: маркеры муцинозных опухолей яичников, раковый антиген (СА 19,9), раково эмбриональный антиген (РЭА). CLINICAL AND MOLECULAR ASPECTS OF MUCINOUS OVARIAN TUMORS: ETIOPATHOGENESIS, INDIVIDUALIZATION OF TREATMENTKedrova AG, Levakov SA, Shablovskiy OR, Wanke NS, Nechaeva OV, Maksimenko TA To determine the prognosis and prognostic factors in series of mucinous tumors of the ovary (MTO) we included 34 patients in our retrospective review. Criteria were defined: 1.centralized his tological review by our expert pathologist; 2. high risk of peritoneal pseudomyxoma or any synchro nous malignant tumor in the abdominal cavity; 3. available data on the management and outcomes of patients. We found specific markers overexpression in mucinous ovarian tumors compared to their normal ovary tissues and serous type ovarian tumors by analysis of serum CA 19,9, CEA and immunohistochemistry. These results suggest that mucinous tumors of the ovary have distinctive cancergenesis and may attribute to the progression of the mucinous ovarian cancer.Key words: markers overexpression in mucinous ovarian tumors, cancer antigen (CA 19,9), can cer embryonic antigen (CEA).

show abstract

Can Patients With Relapsed, Previously Untreated, Stage I Epithelial Ovarian Cancer Be Successfully Treated With Salvage Therapy?

Cited by 35 publications

References 9 publications

Prognostic Factors and Clinical Outcome of Patients With Recurrent Early-Stage Epithelial Ovarian Cancer: An Italian Multicenter Retrospective Study

Prognostic Factors and Clinical Outcome of Patients With Recurrent Early-Stage Epithelial Ovarian Cancer: An Italian Multicenter Retrospective Study

Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer

Clinical and Molecular Aspects of Mucinous Ovarian Tumors: Etiopathogenesis, Individualization of Treatment

Contact Info

Product

Resources

About